Literature DB >> 26586398

Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype.

Hee-Young Jeon1,2, Jun-Kyum Kim1,2, Seok Won Ham1, Se-Yeong Oh3, Jaebong Kim4, Jae-Bong Park4, Jae-Yong Lee4, Sung-Chan Kim5, Hyunggee Kim6,7.   

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive and fatal primary brain tumors in humans. The standard therapy for the treatment of GBM is surgical resection, followed by radiotherapy and/or chemotherapy. However, the frequency of tumor recurrence in GBM patients is very high, and the survival rate remains poor. Delineating the mechanisms of GBM recurrence is essential for therapeutic advances. Here, we demonstrate that irradiation rendered 17-20 % of GBM cells dead, but resulted in 60-80 % of GBM cells growth-arrested with increases in senescence markers, such as senescence-associated beta-galactosidase-positive cells, H3K9me3-positive cells, and p53-p21(CIP1)-positive cells. Moreover, irradiation induced expression of senescence-associated secretory phenotype (SASP) mRNAs and NFκB transcriptional activity in GBM cells. Strikingly, compared to injection of non-irradiated GBM cells into immune-deficient mice, the co-injection of irradiated and non-irradiated GBM cells resulted in faster growth of tumors with the histological features of human GBM. Taken together, our findings suggest that the increases in senescent cells and SASP in GBM cells after irradiation is likely one of main reasons for tumor recurrence in post-radiotherapy GBM patients.

Entities:  

Keywords:  Glioblastoma multiforme; Radiotherapy; Recurrence; Senescence; Senescence-associated secretory phenotype

Mesh:

Substances:

Year:  2015        PMID: 26586398     DOI: 10.1007/s13277-015-4439-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

Review 1.  New advances that enable identification of glioblastoma recurrence.

Authors:  Isaac Yang; Manish K Aghi
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

2.  In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.

Authors:  James B Mitchell; Rajani Choudhuri; Kristin Fabre; Anastasia L Sowers; Deborah Citrin; Sonya D Zabludoff; John A Cook
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

3.  Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Authors:  Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

4.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

5.  Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy.

Authors:  B C Liang; A F Thornton; H M Sandler; H S Greenberg
Journal:  J Neurosurg       Date:  1991-10       Impact factor: 5.115

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 7.  Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.

Authors:  Julie E Chang; Deepak Khuntia; H Ian Robins; Minesh P Mehta
Journal:  Clin Adv Hematol Oncol       Date:  2007-11

Review 8.  Four faces of cellular senescence.

Authors:  Francis Rodier; Judith Campisi
Journal:  J Cell Biol       Date:  2011-02-14       Impact factor: 10.539

9.  Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.

Authors:  Jean-Philippe Coppé; Christopher K Patil; Francis Rodier; Yu Sun; Denise P Muñoz; Joshua Goldstein; Peter S Nelson; Pierre-Yves Desprez; Judith Campisi
Journal:  PLoS Biol       Date:  2008-12-02       Impact factor: 8.029

10.  A complex secretory program orchestrated by the inflammasome controls paracrine senescence.

Authors:  Juan Carlos Acosta; Ana Banito; Torsten Wuestefeld; Athena Georgilis; Peggy Janich; Jennifer P Morton; Dimitris Athineos; Tae-Won Kang; Felix Lasitschka; Mindaugas Andrulis; Gloria Pascual; Kelly J Morris; Sadaf Khan; Hong Jin; Gopuraja Dharmalingam; Ambrosius P Snijders; Thomas Carroll; David Capper; Catrin Pritchard; Gareth J Inman; Thomas Longerich; Owen J Sansom; Salvador Aznar Benitah; Lars Zender; Jesús Gil
Journal:  Nat Cell Biol       Date:  2013-06-16       Impact factor: 28.824

View more
  22 in total

Review 1.  Multiple functions of p21 in cancer radiotherapy.

Authors:  Yanbei Kuang; Jian Kang; Hongbin Li; Bingtao Liu; Xueshan Zhao; Linying Li; Xiaodong Jin; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

Review 2.  Cancer-Incidence, prevalence and mortality in the oldest-old. A comprehensive review.

Authors:  Shantell C Nolen; Marcella A Evans; Avital Fischer; Maria M Corrada; Claudia H Kawas; Daniela A Bota
Journal:  Mech Ageing Dev       Date:  2017-05-11       Impact factor: 5.432

3.  Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging.

Authors:  Denise P Muñoz; Steven M Yannone; Anneleen Daemen; Yu Sun; Funda Vakar-Lopez; Misako Kawahara; Adam M Freund; Francis Rodier; Jennifer D Wu; Pierre-Yves Desprez; David H Raulet; Peter S Nelson; Laura J van 't Veer; Judith Campisi; Jean-Philippe Coppé
Journal:  JCI Insight       Date:  2019-06-11

4.  Targeting cellular senescence in cancer and aging: roles of p53 and its isoforms.

Authors:  Jessica Beck; Casmir Turnquist; Izumi Horikawa; Curtis Harris
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

Review 5.  Sexual Differentiation Specifies Cellular Responses to DNA Damage.

Authors:  Lauren Broestl; Joshua B Rubin
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

6.  Sodium butyrate induces senescence and inhibits the invasiveness of glioblastoma cells.

Authors:  Hidemitsu Nakagawa; Satoru Sasagawa; Kazuyuki Itoh
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

7.  Induction of senescence in primary glioblastoma cells by serum and TGFβ.

Authors:  Ritesh Kumar; Alexander Gont; Theodore J Perkins; Jennifer E L Hanson; Ian A J Lorimer
Journal:  Sci Rep       Date:  2017-05-19       Impact factor: 4.379

Review 8.  An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.

Authors:  Elzbieta Pawlowska; Joanna Szczepanska; Magdalena Szatkowska; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2018-03-17       Impact factor: 5.923

Review 9.  Paracrine roles of cellular senescence in promoting tumourigenesis.

Authors:  Jose Mario Gonzalez-Meljem; John Richard Apps; Helen Christina Fraser; Juan Pedro Martinez-Barbera
Journal:  Br J Cancer       Date:  2018-04-19       Impact factor: 7.640

10.  Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.

Authors:  Daqian Zhan; Ding Ma; Shuang Wei; Bachchu Lal; Yi Fu; Charles Eberhart; John Laterra; Mingyao Ying; Yunqing Li; Alan Meeker; Hernando Lopez-Bertoni; Shuli Xia
Journal:  Mol Cancer Res       Date:  2021-08-04       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.